LENZ Therapeutics Inc (LENZ)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $129.77M
Last updated: Nov 17, 2026 at 11:05 AM ET
LENZ Therapeutics Inc (LENZ) Earnings: Report Dates and Results
LENZ Therapeutics (LENZ) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, LENZ Therapeutics reported EPS of -$0.99, below the -$0.97 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LENZ has an expected report date of Mar 22, 2027.
LENZ Earnings Call
The latest LENZ earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 21 quarters below that had an estimate, LENZ beat 8, missed 12 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $3.38M, down 73.0% from $12.50M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.99 | -$0.97 | -$1.02 - -$0.85 | -2.06% | Miss | N/A | 6 | 4 up, 3 down | Oct 28, 2026 | $3.38M |
| Jun 30, 2026 | -$1.02 | -$1.21 | -$1.37 - -$0.53 | +15.70% | Beat | N/A | 7 | 0 up, 2 down | Aug 11, 2026 | $5.49M |
| Mar 31, 2026 | -$1.32 | -$1.07 | -$1.25 - -$0.56 | -23.31% | Miss | N/A | 7 | 0 up, 3 down | May 11, 2026 | $1.90M |
| Dec 31, 2025 | -$1.16 | -$0.92 | -$1.04 - -$0.70 | -26.09% | Miss | N/A | 6 | 2 up, 0 down | Mar 24, 2026 | $1.59M |
| Sep 30, 2025 | -$0.59 | -$0.67 | -$0.94 - -$0.43 | +11.94% | Beat | N/A | 6 | 2 up, 2 down | Nov 5, 2025 | $12.50M |
| Jun 30, 2025 | -$0.53 | -$0.54 | -$0.77 - -$0.37 | +1.85% | Beat | N/A | 5 | 0 up, 0 down | Jul 30, 2025 | $5.00M |
| Mar 31, 2025 | -$0.53 | -$0.32 | -$0.32 - -$0.32 | -65.63% | Miss | N/A | 1 | 0 up, 0 down | May 7, 2025 | N/A |
| Dec 31, 2024 | -$0.46 | -$0.42 | N/A | -9.52% | Miss | N/A | 2 | 1 up, 1 down | Mar 19, 2025 | $66000 |
| Sep 30, 2024 | -$0.38 | -$0.43 | -$0.59 - -$0.41 | +11.63% | Beat | N/A | 5 | 0 up, 0 down | Nov 6, 2024 | N/A |
| Jun 30, 2024 | -$0.40 | -$0.67 | -$0.67 - -$0.40 | +40.30% | Beat | N/A | 4 | 0 up, 0 down | Aug 14, 2024 | N/A |
| Mar 31, 2024 | -$3.53 | -$0.82 | -$1.28 - -$0.50 | -330.49% | Miss | N/A | 3 | 0 up, 0 down | May 8, 2024 | N/A |
| Dec 31, 2023 | -$0.40 | -$0.13 | N/A | -207.69% | Miss | N/A | N/A | N/A | Feb 27, 2024 | N/A |
| Sep 30, 2023 | -$0.24 | -$0.24 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 13, 2023 | N/A |
| Jun 30, 2023 | -$6.79 | -$6.79 | N/A | -0.03% | Miss | N/A | N/A | N/A | Sep 11, 2023 | N/A |
| Mar 31, 2023 | -$3.01 | -$2.77 | N/A | -8.70% | Miss | N/A | N/A | N/A | Jun 28, 2023 | N/A |
| Dec 31, 2022 | -$3.08 | -$3.45 | N/A | +10.81% | Beat | N/A | N/A | N/A | Mar 29, 2023 | N/A |
| Sep 30, 2022 | -$3.15 | -$3.11 | N/A | -1.31% | Miss | N/A | N/A | N/A | Dec 29, 2022 | N/A |
| Jun 30, 2022 | -$3.36 | -$3.44 | N/A | +2.27% | Beat | N/A | N/A | N/A | Sep 28, 2022 | N/A |
| Mar 31, 2022 | -$3.36 | -$2.73 | N/A | -23.11% | Miss | N/A | N/A | N/A | Jun 28, 2022 | N/A |
| Dec 31, 2021 | -$2.45 | -$2.08 | N/A | -17.68% | Miss | N/A | N/A | N/A | Mar 29, 2022 | N/A |
| Sep 30, 2021 | -$0.06 | -$0.28 | N/A | +78.32% | Beat | N/A | N/A | N/A | Dec 29, 2021 | N/A |
| Jun 30, 2021 | -$24.15 | -$0.29 | N/A | N/A | N/A | N/A | N/A | N/A | Sep 28, 2021 | N/A |
| Mar 31, 2021 | -$0.34 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 28, 2021 | N/A |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.81, after -$4.77 the year before. It was -$27.00 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.81 | N/A |
| Dec 31, 2024 | -$4.77 | N/A |
| Dec 31, 2023 | -$10.44 | N/A |
| Dec 31, 2022 | -$12.95 | N/A |
| Dec 31, 2021 | -$27.00 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,470 | 11 | |
| 2026Q2 | Jun 30, 2026 | 4,734 | 8 | |
| 2026Q1 | Mar 31, 2026 | 5,511 | 11 | |
| 2025Q4 | Dec 31, 2025 | 8,881 | 10 | |
| 2025Q3 | Sep 30, 2025 | 7,630 | 12 | |
| 2025Q1 | Mar 31, 2025 | 7,248 | 12 | |
| 2024Q4 | Dec 31, 2024 | 6,259 | 12 | |
| 2024Q3 | Sep 30, 2024 | 6,021 | 12 |
2026Q3 Earnings Call
Opening remarks
Dan Chevallard CFO Thank you, Tina. Good morning, and thank you for joining us today. My name is Dan Chevallard, Chief Financial Officer of LENZ Therapeutics. We are joined today by Eef Schimmelpennink, our President and Chief Executive Officer, Shawn Olsson, our Chief Commercial Officer, and Dr. Marc Odrich, our Chief Medical Officer. Before we begin, I would like to remind you that this call will contain forward-looking statements regarding LENZ's future expectations, plans, prospects, corporate strategy, regulatory and commercial plans and expectations, cash runway projections, and performance. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors and risks, including those discussed in our filings with the SEC, and which can also be found on our website. In addition, any forward-looking statements represent only our views as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. The company encourages you to consult the risk factors contained in our SEC filings for additional detail. With that, I'll now turn the call over to Eef.
Eef Schimmelpennink CEO Thank you, Dan. Good morning, everyone. Today's results mark an important step forward for LENZ and VIZZ. In the third quarter, we saw more than 50% growth in both product revenue and total prescriptions, with strong momentum continuing into the fourth quarter. On October 1st, we marked the one-year anniversary of the VIZZ launch. Over the past year, we've built important foundations, gained valuable insights into what drives adoptions, and, importantly, drove encouraging momentum from our consumer-focused initiatives. This last quarter, we continued to see that consumer demand generation is a key driver of growth. Expanding our Tired of Reading Glasses campaign to national TV enabled us to reach a broader group of consumers with a clear message around an alternative to reading glasses. Our newly established telehealth channel also gives interested consumers a convenient path to evaluation by an independent licensed eye care professional and, when appropriate, a prescription with home delivery. Together, these initiatives have helped establish a more seamless path from awareness to evaluation, treatment, and continued use. As I mentioned, the results were more than 50% growth in product revenue and total prescriptions in the third quarter, with strong momentum carrying into the early weeks of Q4. We have built a strong foundation with eye care professionals. VIZZ awareness now exceeds 90%, with more than 15,000 prescribing ECPs. At the same time, our launch experience has shown that physician awareness alone is not sufficient to drive adoption at the pace we want.
Frequently Asked Questions About LENZ
When is LENZ Therapeutics's next earnings date?
LENZ Therapeutics's next earnings report is expected for Mar 22, 2027.
Did LENZ beat earnings estimates last quarter?
No. LENZ Therapeutics reported EPS of -$0.99 for the quarter ended Sep 30, 2026, below the -$0.97 estimate by 2.06%.
What EPS do analysts expect from LENZ next quarter?
The consensus EPS estimate for LENZ Therapeutics for the quarter ending Dec 31, 2026 is -$0.91 from 9 analysts, with estimates from -$1.22 to -$0.67.
How often does LENZ beat earnings estimates?
LENZ Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -12.14%.
LENZ pages: Overview, Earnings, Forecast, Financials, Competitors